Deutsche Bank Ag\ Neu Base Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	BUY	$4.63 - $7.34 $408,829 - $648,122	88,300 Added 754.7%	100,000 $479,000
Q1 2021 May 13, 2021	SELL	$6.92 - $12.36 $7,079 - $12,644	-1,023 Reduced 8.04%	11,700 $86,000
Q4 2020 Feb 16, 2021	BUY	$6.92 - $9.25 $20,676 - $27,639	2,988 Added 30.69%	12,723 $89,000
Q3 2020 Nov 12, 2020	BUY	$7.25 - $9.71 $6,126 - $8,204	845 Added 9.51%	9,735 $74,000
Q2 2020 Aug 13, 2020	BUY	$6.69 - $11.51 $59,474 - $102,323	8,890 New	8,890 $78,000
Q1 2020 May 14, 2020	SELL	$4.77 - $8.23 $25,805 - $44,524	-5,410 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.5 - $8.1 $24,345 - $43,821	5,410 New	5,410 $38,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.